Nachrichten zur Sarepta Therapeutics Aktie

Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript

SRPT earnings call for the period ending March 31, 2024.…

Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript

…

Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy

…

Sarepta Therapeutics: Another Hold Call Ahead Of Some Key Catalysts

…

5 Small Biotech ETFs to Watch (Updated 2024)

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants…

Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst

The upcoming regulatory decision on its latest drug could be big.…

UBS raises Sarepta Therapeutics shares target on label outlook By Investing.com

UBS raises Sarepta Therapeutics shares target on label outlook…

Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript

SRPT earnings call for the period ending December 31, 2023.…

Sarepta Therapeutics, Inc. (SRPT) Q4 2023 Earnings Call Transcript

…

Is It Too Late to Buy Sarepta Therapeutics Stock?

The companys hyperfocus on its core area could continue to be highly lucrative.…

The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron

Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron are included in this Analyst Blog.…

Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?

Its always tough to be compared to a giant.…

Sarepta Therapeutics: Leading The Way In DMD Treatment With Gene Therapy Innovations

…

Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today

One pundit feels there is solid potential in one of the companys more recently approved drugs.…

Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval

…

Sarepta Therapeutics (SRPT) Surges 16.7%: Is This an Indication of Further Gains?

Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions…

Sarepta Therapeutics shares rally, Mizuho says confidence in label expansion remains unwavering By Investing.com

Sarepta Therapeutics shares rally, Mizuho says confidence in label expansion remains unwavering…

Sarepta Therapeutics provides Q4 and FY forecast

…

Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?

Both develop medicines for rare diseases, and each aims to conquer a niche market.…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

SRPT LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT

NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Sarepta Therapeutics: Strong Q3 Earnings Help Offset Overblown Clinical Data Concerns

…

Is Sarepta Therapeutics Stock a Bad-News Buy?

Analysts still expect some sizable returns from the stock.…

Is Sarepta Therapeutics Stock a Bad-News Buy? @themotleyfool #stocks $SRPT

Analysts still expect some sizable returns from the stock.…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Sarepta Therapeutics (SRPT) Q3 2023 Earnings Call Transcript

SRPT earnings call for the period ending September 30, 2023.…

SRPT INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues…

Sarepta Therapeutics, Inc. (SRPT) Q3 2023 Earnings Call Transcript

…

Sarepta Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation

…

Sarepta Therapeutics GAAP EPS of -$0.46 beats by $0.80, revenue of $331.8M beats by $45.03M

…

Sarepta Therapeutics Q3 2023 Earnings Preview

…

Sarepta Therapeutics, Petmed Express among healthcare movers

…

Sarepta Therapeutics crushed after EMBARK misses primary endpoint, promoting 2 downgrades By Investing.com

Sarepta Therapeutics crushed after EMBARK misses primary endpoint, promoting 2 downgrades…

: Sarepta Therapeutics shares plunge as gene therapy trial falls short of primary goal

Company plans to seek label expansion for Duchenne muscular dystrophy treatment…

How to Invest in Genetics (Updated 2023)

Genetics is the study of genes, their variations and hereditary characteristics, as well as how these traits are passed on…

Capricor Therapeutics, Sarepta Therapeutics: A Promising Clinical-Stage Biotech And A Commercial-Stage Leader In Duchenne Muscular Dystrophy

…

dpa-AFX ProFeed